azelnidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	272	123524-52-7

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

azelnidipine
calblock
CS-905

Molecular weight: 582.66
Formula: C33H34N4O6
CLOGP: 6.96
LIPINSKI: 2
HAC: 10
HDO: 2
TPSA: 137.03
ALOGS: -5.85
ROTB: 11

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK,ZAP70	48
kinase-selectivity-class	AXL,BRAF,GRK2,PIK3CD,TEK	5
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Compartment syndrome	110.92	37.06	20	885	2892	90624650
Angioedema	52.93	37.06	21	884	64855	90562687

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	47.36	28.95	23	925	51544	42568843
Cerebral infarction	38.23	28.95	17	931	31152	42589235
Arteriospasm coronary	35.68	28.95	10	938	4728	42615659
Interstitial lung disease	33.18	28.95	21	927	78441	42541946
Renal impairment	31.17	28.95	23	925	110205	42510182

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	70.70	27.58	29	2040	51809	110535421
Hepatic function abnormal	67.36	27.58	33	2036	89262	110497968
Compartment syndrome	53.93	27.58	14	2055	5896	110581334
Renal impairment	49.10	27.58	35	2034	188410	110398820
Cardiac failure	38.05	27.58	30	2039	187596	110399634
Interstitial lung disease	32.00	27.58	24	2045	139310	110447920
Arteriospasm coronary	30.92	27.58	10	2059	9090	110578140
Platelet count decreased	30.74	27.58	29	2040	230414	110356816
Aortic dissection	27.81	27.58	8	2061	4925	110582305

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.74	Basic
pKa2	1.78	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated L-type calcium channel	Ion channel	Q01668 Q13936	CAC1D_HUMAN CAC1C_HUMAN	BLOCKER				DRUG LABEL	KEGG DRUG

External reference:

ID	Source
D01145	KEGG_DRUG
C0753287	UMLSCUI
CHEBI:31247	CHEBI
CHEMBL1275868	ChEMBL_ID
DB09230	DRUGBANK_ID
C061679	MESH_SUPPLEMENTAL_RECORD_UI
7109	INN_ID
PV23P19YUG	UNII
65948	PUBCHEM_CID

Pharmaceutical products:

None